

Newsletter

Edition 44 | Winter – Spring 2020

The COVID-19 pandemic has caused considerable hardship for women undergoing breast cancer treatment and those living with metastatic disease. At the height of the pandemic, Marie Pandeloglou shared how her life has been impacted.

Five years ago when I thought I was in remission from my breast cancer diagnosis, I received the devastating news that my cancer had come back. That nagging cough and change in voice was not the flu. It was cancer – breast cancer cells had spread to my lungs initially, and then to my liver and more recently to the brain which means I am now living with stage IV, or metastatic, breast cancer.

Living with metastatic breast cancer has been extremely challenging; the surgeries, radiotherapy sessions, chemotherapy and hormone therapy. But it has become even harder now.

COVID-19 is a real risk for me and many others in my position. I am considered high-risk as I am undergoing active treatment for my cancer.

I am currently having chemotherapy for my cancer and my oncologists treatment decisions have been influenced by this ongoing pandemic. She has chosen a form of chemotherapy that means I have less contact time in the hospital and more time taking oral chemotherapy where I can stay safely at home. I am also taking injections to help increase my white cell count, something that would not be necessary before COVID-19 but is now essential.



I am so impressed by the precautions taken by my hospital and treatment team, but for it to make a real difference for me, I need everyone in my community to step up. I have to take this seriously, as my life depends on it. It is hard, but it is necessary.



A special time for Marie was her daughter's wedding. She is pictured here with both her daughters at the bridal shower in 2018.

The isolation is lonely. Where once I was able to have my family and friends share a laugh in the chemotherapy ward or a visit at home, I am now in isolation going through the chemotherapy symptoms alone and waiting anxiously for my husband to return from work.

Living with metastatic breast cancer means every day is a gift that I'm still here. However, not being able to hug my daughters and parents, who don't live with me, is very difficult and sad.

I'm staying home self-isolating during the day, having groceries delivered each day and sanitising every single thing that comes into my home. When my husband gets home from his job the first thing he does, even before I get a kiss, is he changes his clothes and showers immediately. When we walk our dog, we wear masks and wave to neighbours from afar.

What worries me is how people respond to the virus and the various measures put in place to limit its transmission. I can't stress enough just how important it is to follow the government guidelines applicable in your State, adopt good hand hygiene and practise social distancing even among family and close friends. This isn't just for you, but about all of us. We need to work together to get control of this virus.

Marie



When I last wrote to you in January, little did we know what lay ahead and that our world would soon change forever. The COVID-19 pandemic has certainly been a challenging time and I do hope you are safe and well. As I write to you, the situation continues to unfold highlighting that we must continue to work together, adhering to social distancing and government rules and restrictions in our areas, to stop and slow the spread of COVID-19.

I'm pleased to report that there has been minimal interruption to the overall conduct of our clinical trials research program, which is generously supported by you. Our researchers, located in hospitals and medical institutions throughout Australia and New Zealand, adapted their work practices and patient treatment plans during the height of the pandemic to ensure the safety of their breast cancer patients including those enrolled to our clinical trials. And in June, thanks to your donations and the hard work of our research team, we were able to launch two new clinical trials, CAPTURE and Neo-N. I look forward to keeping you informed about these trials as they progress.

Following a three-month period of working from home, our workforce returned to the office on 6 July. We are now a designated COVID-19 safe workplace and the health and safety of our staff remains of utmost importance. We look forward to continuing to provide you, our valued supporters, with the services you deserve.

Importantly, the adaptation of systems and processes to manage our research and fundraising activities in response to the pandemic, has highlighted new opportunities and initiatives we look forward to pursuing. As always, we remain committed to saving every life from breast cancer.

As you may know, a breast cancer diagnosis is distressing at any time. This is being felt acutely now by people due to the increased risk of COVID-19, and by those who have metastatic breast cancer who are particularly vulnerable, like Marie whose story appears in this newsletter.

That's why I'm so grateful for your continued commitment to our research program and the many people it benefits. Together we can continue to save and improve lives.

Professor Bruce Mann
Board Chair, Breast Cancer Trials

Bequests

We gratefully acknowledge bequests received from the following supporters and offer our condolences to their families:

Ms Janice Ethel Berwick
Mr Gilroy John Brophy
Miss Kathleen Cotes

Ms Irene Pearl Haigh
Mrs Joan Mary McGillivray
Mr Allan Rowling

Miss Gwenyth K Vitnell
Mr Peter Webb
Estate of the Late James
O Fairfax AC

Remembering Breast Cancer Trials in your Will ensures that the special commitment you have to save lives from breast cancer today, is a legacy which will continue beyond your life time.

If you would like information about leaving a gift in your Will, please tick the box on your donation slip or contact Cheryl our Special Gifts Officer for a confidential discussion on 1800 423 444.

In Memoriam

We gratefully acknowledge gifts received in memory of:

Mrs Kate Anderson	Mrs Myra Gentle	Mrs Vivien McKenzie	Mrs Galina Rabinovich
Mrs Delwyn Arthur	Mrs Lorna Graham	Mrs Barbara McMullen	Mrs Marian Coleman
Mrs Del Steward	Mrs Evelyn Harris	Mrs Betty Tindall	Mrs Ivy Dodd
Mrs Madeleine Backes	Mrs Jocelyn Harris	Ms Karen Barnett	Mrs Suzanne Pearl
Mrs Danya Ellinghaus	Mr Geoff Hawker	Mrs Rhonda Moffatt	Mrs Mary Roberts
Mrs Susan Boswell	Mrs Kathy Healey	Mrs Michelle Morris	Ms Meagan Nesbitt
Mrs Margaret Bowman	Ms Susan Hiskins	Mrs Lauren Koppers	Mrs Sheila Evans OAM
Ms Maureen Abraham	Mrs Shakuntla Devi	Ms Rubina Rehan	Mrs Marion Ratzmer
Mrs Gladys Brockwell	Mrs Angelina Cherubino	Mrs Joyce Morton	Mrs Luigia Ruscio
Mrs Susan Byfield	Mrs Marjorie Culkin	Mrs Christine Faber	Ms Christina Rutledge
Mrs Betty Jean Campbell	Mrs Isabel Hodgson	Mrs Trish Nash	Ms Dawn Wyatt
Ms Odette Capobianco	Mrs Thea Etherington	Mrs Wendy Bingham	Mrs Ann Newman
Mrs Stella Vanasse-Bouffard	Mrs Pamela Horadam	Mrs May Clark	Mrs Helen Black
Mrs Rosa Carbone	Mrs Sarah James	Mrs Michelle Cox	Mrs Sue Shirlaw
Mrs Val Connors	Mrs Veronica Januszke	Mrs Monica Jordan	Mrs Marie Maguire
Mrs Sue Cherry	Mrs Clara Santini Marcon	Mrs Eileen Moore	Mrs Margaret Brodie
Mrs Marilyn O'Brien	Mrs Jeanette Jenkin	Mrs Tracy Nicholls	Mrs Joan Cresswell
Mrs Jenny Pierce	Mrs Karen Johnson	Mrs Patricia Shanahan	Mrs Toni Graves
Mrs Rona Plummer	Mrs Julie Jones	Ms Sandra Murray	Mrs Maria Elisabetta Murdocca
Mrs Lyndsey Clark	Mrs Maya Katz	Mrs Bhanu Padmashiri	Mrs Beryle Rolfe
Ms Pat Wong	Mrs Marian Kemp	Mrs Annie Parkinson	Mrs Ngairé Sperry
Ms Kellie Clayton	Mrs Alinda Seoud	Mrs Julie Leighton	Mrs Julia Squadrito
Mrs Christie Clifton	Mrs Dorothy Kerr	Ms Marie Amos	Mrs Hilda Stewart
Mrs Mandy Cosmos	Mrs Sharon Kruger	Mrs Margaret Christy	Mrs Carol Stirling
Miss Paige Crossingham	Mrs Jean Toon	Ms Ellouise Desailley	Mr David Sweeney
Mrs Sally Saliba	Mrs Sandra Lalovic	Mrs Carol Bastian	Mrs Carol Sielaff
Mrs Jean Thomson	Mrs Dorothy Laney	Mrs Mary Bootle	Mrs Karel Dutton
Mrs Jan Cox	Mrs Margaret Bellamy	Ms Carla Gallus	Mrs June Thomas
Mrs Georgina Crawford	Ms Suzanne Florance	Mrs Jane Halliday	Mrs Demi Mak
Mrs Karen Crownover	Mrs Chris Lane	Mrs Bette Beryl Paterson	Mrs Rina Traficante
Mr Alan Dale	Mrs Rosa Tosto	Mrs Ann-Marie Atkinson- Keane	Mrs Denise Visbeen
Ms Patricia De Piazza	Mrs Gladys Jean Langlands	Mrs Heather Pezely	Mrs Beverley Beshara
Mr Rory Chisholm	Mrs Hilda Larcombe	Mrs Rosina Deverson	Mrs Evelyn Mason
Mrs Julie Devine	Mrs Kim Leckey	Mrs Doras Pill	Mr Ravinder Sapra
Mrs Mavis Dixon	Mrs Barbara Anderson	Mrs Gladys Maunder	Mrs Siska Visbeen
Mrs Margaret Dwyer	Ms Olga Lihou	Mrs Natalia Prihodchenko	Ms Deana Walker
Mrs Claire Edwards	Mrs Christina Livas	Mrs Karyn Williams	Mrs Florence Whittick
Mrs Arley Ellemor	Mrs Carmelita Mana	Mrs Thelma Wright	Mrs Maxine Winter
Mrs Christeen Englert	Mrs Karen Barber	Mrs Sylvia Prisk	Ms K S Wong
Ms Gina Fallon	Mrs Jovita Manick	Mrs Jane McLoughlin	Ms Chun Wong
Ms Sheree Fowler	Mrs Jill McFarlane	Mrs Patty Purves	
Mrs Sandy Fuller	Mrs Shirley McKenzie	Mrs Dawn Ashworth	

Join the 3 Course Challenge and cook up a cure for breast cancer

Things are feeling a little French around here because we've just launched a *très magnifique* event with top Australian chef and master of French cuisine Manu Feildel!

Like you, Manu is a passionate supporter of Breast Cancer Trials. He truly understands the importance of our research as his beautiful mum, Evelyne, was diagnosed with breast cancer earlier this year.



Manu and mum Evelyne.

So, to protect his mum and all women facing breast cancer, Manu is hosting the 3 Course Challenge, an exciting new event for supporters like you!

This challenge of life-saving proportions (or should we say portions 😊) invites you to cook a three-course French menu and host a dinner party with a difference.

Ask your friends and family to support you in this challenge by donating to our life-saving breast cancer trials research.

Manu will be right by your side (virtually of course). He's created a special menu for the event and will show you how to cook it in his livestreamed interactive cooking class on August 29.

We'll provide you with all the elements you need to make your event a fun French feast including access to a French Music Playlist on Spotify, templates for invitations and French games to play.

With current international travel restrictions in place, we hope the 3 Course Challenge can bring a touch of France to Australian homes this August, and a reason for family and friends to get together to share in some good food for a very good cause.

Registration is now open for the event. Sign up today at www.3coursechallenge.com.au and start planning your *délicieux* dinner party!



The diary that saves lives

The Australian Women's Health Diary, in its 23rd year, remains an informative and much-loved organiser for women. The 2020 edition raised \$900,000! Every dollar helps fund our breast cancer trials research program to make possible advances which can save lives.

Available from 1 October, the 2021 edition is again packed with health information for women of all ages, wrapped in a practical, easy to use diary format. A beautiful, eye-catching cover shows off the new book-bind format, replacing the traditional spiral bind and making the diary more compact and user friendly.

Priced at just \$18.95, it will be available from 1 October in newsagents, Woolworths, participating post offices and our website at breastcancertrials.org.au. Your special offer will be available in September.



Research update

The American Society of Clinical Oncology (ASCO) congress is the largest cancer conference in the world, bringing together the world's most reputable cancer researchers, patient advocates and industry professionals, including those from Breast Cancer Trials, to discuss the latest advancements in cancer treatments, clinical trials research and cancer care.

This year, due to COVID-19 restrictions, the conference went online, with delegates logging in at all hours of the day around the world to attend sessions and lectures. Here is a summary of the key worldwide breast cancer clinical trials research, and how this research is driving the clinical trials you're generously supporting.

Positive survival data for metastatic triple negative breast cancer

The KEYNOTE355 clinical trial was a phase three trial that evaluated an immunotherapy drug pembrolizumab, in combination with (one of three) chemotherapy drug treatments, compared to those chemotherapy drugs alone. This trial was open to patients with inoperable locally recurrent or metastatic triple negative breast cancer. This means the patients' cancer has come back after treatment or has spread to other parts of the body and is unable to be removed in an operation.

Results presented at ASCO 2020 show that in patients with programmed cell death ligand (PD-L1) positive tumours with a combined positive score equal to or more than 10, the immunotherapy plus chemotherapy treatment led to a statistically significant and clinically meaningful improvement in the amount of time patients lived without worsening of their cancer. This combination of treatment reduced the risk of disease progression or death by 35% and improved the progression-free survival to an average of 9.7 months compared to the 5.6 months for patients receiving only chemotherapy. There were some additional, manageable, immune related side effects seen with pembrolizumab.

Because the immunotherapy drug, pembrolizumab, used in the clinical trial targets PD-L1 positive tumours, the researchers and clinicians who worked on this trial believe that if approved, the addition of this new treatment could provide a new option for these patients with hard-to-treat triple negative breast cancer.

"The use of immunotherapy drugs in the treatment of some cancers such as melanoma has shown significant success. We aim to identify how best to use immunotherapy in the treatment of breast cancer. Latest research indicates that earlier immunotherapy use in the treatment plan may provide better

outcomes for patients. Our new Neo-N clinical trial, supported with your kind donations, is therefore critically important because it is evaluating giving immunotherapy with chemotherapy prior to surgical removal of the breast cancer in patients with early stage triple negative breast cancer. It could provide evidence that immunotherapy given early can cure more patients and spare them from some of the worst side effects of chemotherapy."

Dr Nick Zdenkowski, Breast Cancer Trials Researcher



Dr Nick Zdenkowski,
BCT Researcher and
Medical Oncologist

Improved survival for patients with brain metastases

The HER2CLIMB clinical trial was a randomised phase 2 trial which evaluated the addition of an oral drug, tucatinib, to treatment with capecitabine and trastuzumab in patients with advanced HER2 positive breast cancer that had spread to other parts of the body and was resistant to other HER2-targeted drugs. The primary results of the trial have been published and showed that tucatinib prolongs survival in patients with metastatic HER2 positive breast cancer.

At ASCO 2020, further results from the trial were presented which focused on the HER2 positive patients whose breast cancer had spread (metastasised) to the brain. This type of cancer is often difficult to control when it has spread to the brain, unfortunately resulting in short survival times. It is estimated that about 50% of patients with HER2 positive metastatic breast cancer have brain metastases.

These results were remarkable showing an overall survival benefit in this group of patients. The investigators found that in patients with heavily pre-treated, HER2 positive metastatic breast cancer with brain metastasis, the addition of the drug tucatinib to the combination of trastuzumab and capecitabine doubled the number of patients whose brain tumours shrank, reduced the risk of brain metastasis worsening or death by two-thirds, and reduced the risk of death by half.

"The results from this trial are a breakthrough for this important group of patients who need more treatment options to prolong their lives. Tucatinib was recently approved for use in the United States and it is hoped it will soon be approved for use in Australia too."
Dr Nick Zdenkowski, Breast Cancer Trials Researcher

Treatment combination improves time to disease progression

PIK3CA mutations are found in the tumours of approximately 40% of patients with hormone receptor positive, HER2 negative metastatic breast cancer, and is associated with treatment resistance and poor outcomes.

The BYLIEVE clinical trial treated patients with metastatic hormone receptor positive, PIK3CA mutant breast cancer with the combination of alpelisib and fulvestrant after prior aromatase inhibitor and CDK4/6 inhibitor treatment. The results, presented at ASCO 2020, showed that 50% of patients were alive, and their disease had not progressed, at six months. This represents a meaningful duration of cancer control for these patients with treatment-resistant cancer. Some toxicity was identified (diarrhoea, high blood sugar,

nausea, rash), but few patients stopped alpelisib due to side effects, suggesting that it is manageable.

"This clinical trial result is of great interest because of our CAPTURE clinical trial, recently opened thanks to your support. CAPTURE will use the same combination of alpelisib and fulvestrant in patients with hormone receptor positive HER2 negative metastatic breast cancer who have a PIK3CA mutation in their blood, according to testing of circulating DNA. The BYLIEVE was a single-arm clinical trial, meaning that all patients received the same treatment. Our CAPTURE clinical trial will compare this new treatment combination with the currently used treatment, capecitabine. Comparative clinical trial designs are the accepted gold standard for moving new treatments or treatment combinations towards routine clinical use for the benefit of patients."

Dr Nick Zdenkowski, Breast Cancer Trials Researcher

Keeping families together



It's been wonderful to see the strength and generosity of our breast cancer community during such a challenging start to the year. We can't thank you enough for your kindness and care!

Malea, pictured with her family, featured in our Mother's Day Appeal which, thanks to you, raised funds for the new CAPTURE clinical trial.

"Breast cancer clinical trials create a gateway for people like me to get the best care, and access to medications and treatments. Without enough trials – that can't happen."

Here are just a few of the lovely supporter messages we received:

"Breast cancer has been a part of not only my mum's life, but mine as well. Mum is no longer with us and I miss her every day. Due to clinical trials, I am still alive, healthy and strong... so thank you. Lots of love to all the Mums around the world." – Jenny

"When I was three, my grandmother died at 45 from breast cancer. I am now 73 and I still miss her and what she represented as my grandmother. She has always been with me in spirit but not having her presence in my life, left a huge hole in my heart. Thank you for saving lives." – Dianne

"My donation is for Malea. At 45, I'm three years post diagnosis, with three kids – the fear gets much easier to live with Malea. Just hang in there!" – Tanya

Thanks also for your response to our Tax Appeal which has raised over \$400,000 for the new Neo-N clinical trial. Dai, pictured with her son, featured in the Appeal. She was 46 when diagnosed with breast cancer and says: *"Breast cancer has shown me that so much is out of your control; that life is precious, and you've got to make the most of it. Now, I try to live with courage and help others."*



A very special gift

In February this year, we had the privilege to attend a special function to honour and celebrate the life of Miss Sheila Woodcock. Miss Woodcock was a loyal supporter of Breast Cancer Trials for over 16 years and sadly passed away in 2018.

In the many conversations we shared with Miss Woodcock, she expressed how important breast cancer trials research was to her as she had a friend die of breast cancer and others who had been affected by the disease. Her support throughout her lifetime extended into her passing when she left Breast Cancer Trials a very generous gift of \$450,000 in her Will.

Miss Woodcock had many interests including the arts, cricket, tennis, chocolate and travel and we knew she loved her animals. So it was no surprise to learn at her memorial service that 15 charities were beneficiaries of her Will. These include the Westpac Rescue Helicopter Service, Salvation Army, RSPCA, Vision Australia, Guide Dogs and Scots Kirk Presbyterian Church.

When her cousin asked Miss Woodcock 'Why these charities?', she replied. "Because I've known them for many years or know of them and their work. I have made friends and have seen their appreciation and respect of my support and feel and trust they will use my final gifts well for the benefit our community."

We acknowledge Miss Woodcock's life and her legacy which will continue to positively impact the lives of many people now and in the future.



Miss Woodcock with her beloved cat.



Charity representatives at Miss Woodcock's memorial service.

Remembering Breast Cancer Trials in your Will ensures that the special commitment you have to save lives from breast cancer today, is a legacy which will continue beyond your life time.

If you would like information about leaving a gift in your Will, please tick the box on your donation slip or contact Cheryl our Special Gifts Officer for a confidential discussion on 1800 423 444.

To leave a gift in your Will to Breast Cancer Trials, the following wording should be used:

"I (your name) give to Breast Cancer Trials:

- the residue of my estate, or
- _____% of my estate, or
- the lump sum of \$_____, or
- my property known as _____ [eg, real estate, art works, shares, units or other securities in listed companies]

to be applied for general purposes by Breast Cancer Trials as determined by its directors. I declare that the receipt of an authorised officer of Breast Cancer Trials will be a sufficient discharge to my executors who will not be bound to see the application of this gift."


We promise to listen

Thank you to everyone who completed the 2020 Supporter Survey. We appreciate the goodwill and generosity of our supporters and always listen to, and value, your feedback. You truly are helping to shape the future of your charity and saving lives from breast cancer.


Here's a snapshot of some of the information you shared:

What best describes your motivation to donate to breast cancer trials research?

In response to this question, over half of responders confirmed they have a family member or friend who has been affected by breast cancer. They are the 55 people who are diagnosed with breast cancer in Australia each day. Results from clinical trials save lives in the future, and those who take part in the trials we conduct today can also benefit from having access to a new treatment now. Most responders confirmed an understanding of the importance of clinical trials research and we encourage you to share this knowledge with your family and friends. Your donations really do give certainty and hope when our loved ones need it most.




Areas of breast cancer clinical trials research you are especially interested in.



An overwhelming number of responders confirmed their interest in clinical trials in the area of prevention of breast cancer. Thanks to our supporters, our world first BRCA-P prevention clinical trial has opened in Australia and is currently recruiting participants. This trial will investigate if using a drug called Denosumab can prevent breast cancer in women with a confirmed BRCA1 gene mutation. Many responders also told us they are interested in clinical trials research that can improve quality of life for patients during and after treatment for breast cancer. Chemotherapy is currently the main treatment option available for women with triple negative breast cancer, however it can be difficult to tolerate and can leave many patients with long-term side effects. Thanks to your support, our new clinical trial Neo-N has now commenced, and it is hoped this trial could cure people with triple negative breast cancer and spare them from some of the worst impacts of chemotherapy. To find out more please visit breastcancertrials.org.au

Would you make a monthly gift to Breast Cancer Trials?

Regular, monthly gifts automatically deducted from your bank account or credit card are a simple and effective way to support our research program. These monthly gifts provide a critical base of funding which allows our researchers to pursue research opportunities as they arise. Just over 20% of responders to the survey confirmed they are already members of the Monthly Giving Program or are interested in joining. Thank you! This group of caring people ensure our researchers can move forward quickly when immediate funding is needed, for the benefit of all those affected by breast cancer. If you would like information about becoming a monthly giver, please contact our friendly Supporter Care Team on **1800 423 444** – we would be very happy to hear from you!



Supporters in action

Sarah's marathon effort

You may recognise Sarah Lee who fundraised via her participation in the Paris Marathon last year. This year, Sarah planned to host multiple fundraising events to continue her support for breast cancer trials research. Unfortunately, due to COVID-19, many of Sarah's events had to be cancelled. But that didn't stop Sarah!

She held a 'virtual raffle' which was livestreamed on Facebook, selling 1,300 tickets and raising over \$7,000! Sarah says, "Coronavirus struck and many of my fundraising events had to be cancelled. However, the one thing that keeps me going is that cancer never stops. So, I'm not going to stop either!"

Thank you to Sarah and all our supporters who held virtual fundraising events during the lockdown period raising much needed funds.



Sarah didn't let strict social distancing measures stop her fundraising efforts.

'Pretty in Pink'



In early March, before social distancing restrictions came into place, Olga (pictured) hosted a fabulous 'Pretty in Pink' High Tea to celebrate and cherish the memory of the amazing women in her community who lost their lives too early to breast cancer.

The High Tea was glamorous and fun, with 30 women coming together to raise \$2,200 for research to save lives from breast cancer. Thank you Olga and guests!

If you would like to host a fundraising event, we would love to hear from you. Please visit breastcancertrials.org.au or get in touch at functions@bctrials.org.au

Teeing off from a 'distance'

We know that our wonderful golfers throughout Australia are very excited to get back to playing the game they love now that social distancing restrictions are easing in some locations.

Tee Off for Breast Cancer Trials has been one of the most important fundraising initiatives on our annual calendar since 1997. Over the past few months with many clubs closing during the pandemic, we have understandably not raised the funds normally received at this time of year. But it's fantastic to see many clubs now rescheduling their Tee Off events and using it as a special way to bring their members back together again.

Like Donnybrook Country Club where golfers safely maintained social distancing measures whilst having a fantastic time at their recent Tee Off event which raised \$300.

If you would like to participate in Tee Off 2020, we'd love to hear from you. Please contact us at teeoffenquiries@bctrials.org.au



The members and friends of Donnybrook Club safely kept their distance at their Tee Off event.

Editorial Information

Editor Julie Callaghan, Chief Operating Officer — Fundraising and Philanthropy, Breast Cancer Trials

Contact Details PO Box 283 The Junction, NSW, 2291

Phone (+61) 2 4925 3022 **Freecall** 1800 423 444

Email enquiries@breastcancertrials.org.au

If you would like to be removed from our mailing list, please contact us on the details shown. To see our Privacy Policy visit breastcancertrials.org.au/privacy.

Website breastcancertrials.org.au

ABN 64 051 369 496 **ATO** N0939 **NSW** CFN 10881 **SA** CCP2653 **WA** 20547 **QLD** CH 1436 **ACT** L19000271 **VIC** 10394.18 **TAS** F1A-52